These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 34572745)

  • 1. Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia.
    Campillo-Davo D; Anguille S; Lion E
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor T cell therapies for acute myeloid leukemia.
    Gu B; Chu J; Wu D
    Front Med; 2020 Dec; 14(6):701-710. PubMed ID: 33263835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR'TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment.
    Teppert K; Yonezawa Ogusuku IE; Brandes C; Herbel V; Winter N; Werchau N; Khorkova S; Wöhle C; Jelveh N; Bisdorf K; Engels B; Schaser T; Anders K; Künkele A; Lock D
    Mol Ther Oncol; 2024 Jun; 32(2):200797. PubMed ID: 38601972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The progress and current status of immunotherapy in acute myeloid leukemia.
    Yang D; Zhang X; Zhang X; Xu Y
    Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.
    Mardiana S; Gill S
    Front Oncol; 2020; 10():697. PubMed ID: 32435621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.
    Fan M; Li M; Gao L; Geng S; Wang J; Wang Y; Yan Z; Yu L
    J Hematol Oncol; 2017 Aug; 10(1):151. PubMed ID: 28851445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress and Trend of CAR-T and PD-1 Blockade in the Treatment of Acute Myeloid Leukemia--Review].
    Wang JS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):1069-1074. PubMed ID: 32552984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.
    Marvin-Peek J; Savani BN; Olalekan OO; Dholaria B
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T-Cell Therapy in Hematological Malignancies.
    Haslauer T; Greil R; Zaborsky N; Geisberger R
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
    van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
    Front Immunol; 2020; 11():1804. PubMed ID: 32973756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing Immune Response in Acute Myeloid Leukemia.
    Riva C; Vernarecci C; Minetto P; Goda R; Greppi M; Pesce S; Chies M; Zecchetti G; Ferro B; Maio E; Cea M; Lemoli RM; Marcenaro E; Guolo F
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular immunotherapy for acute myeloid leukemia: How specific should it be?
    Lee JB; Chen B; Vasic D; Law AD; Zhang L
    Blood Rev; 2019 May; 35():18-31. PubMed ID: 30826141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches.
    Ding G; Chen H
    Sci China Life Sci; 2016 Jul; 59(7):673-7. PubMed ID: 27142351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.
    Dao T; Xiong G; Mun SS; Meyerberg J; Korontsvit T; Xiang J; Cui Z; Chang AY; Jarvis C; Cai W; Luo H; Pierson A; Daniyan A; Yoo S; Takao S; Kharas M; Kentsis A; Liu C; Scheinberg DA
    Blood; 2024 Feb; 143(6):507-521. PubMed ID: 38048594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges.
    Kang S; Li Y; Qiao J; Meng X; He Z; Gao X; Yu L
    Front Oncol; 2022; 12():787108. PubMed ID: 35356211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML).
    Acharya UH; Walter RB
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens.
    Akatsuka Y
    Front Immunol; 2020; 11():257. PubMed ID: 32184779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive cell therapy for acute myeloid leukemia.
    Ma H; Padmanabhan Iyer S; Parmar S; Gong Y
    Leuk Lymphoma; 2019 Jun; 60(6):1370-1380. PubMed ID: 30628504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.